Urokinase Inhibitor Design Based on Pharmacophore Model Derived from Diverse Classes of Inhibitors

A three-dimensional pharmacophore model was developed based on 24 currently available inhibitors, which were rationally selected from 472 compounds with diverse molecular structure and bioactivity, for generating pharmacophore of uPA (Urokinase Plasminogen Activator) inhibitors. The best hypothesis (Hypo1) comprised of five features, namely, one positive ionizable group, one hydrogen-bond acceptor group and three hydrophobic aromatic groups. The correlation coefficient, root mean square deviation and cost difference were 0.973, 0.695, and 94.291 respectively, suggesting that a highly predictive pharmacophore model was successfully obtained. The application of the model showed great success in predicting the activities of 251 known uPA inhibitors (test set) with a correlation coefficient of 0.837, and there was also none of the outcome hypotheses that had similar cost difference and RMS deviation (RMSD) with that of the initial hypothesis generated by Cat-Scramble validation test with 95% confidence level. Accordingly, our model should be reliable in identifying structurally diverse compounds with desired biological activity. Corresponding Author: Keun Woo Lee (Email: kwlee@ gnu.ac.kr). This work was supported by grants from the MOST/KOSEF to the Environmental Biotechnology National Core Research Center (R15-2003-012-02001-0) and the Basic Research Program (R01-2005-000-10373-0), Korea.

[1]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[2]  M. Duffy.  Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. , 2001, Biochemical Society transactions.

[3]  A. Sappino,et al.  Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints , 1997, Annals of the rheumatic diseases.

[4]  V. A. Horne,et al.  Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. , 2002, Bioorganic & medicinal chemistry letters.

[5]  Jean M. Severin,et al.  Identification of novel inhibitors of urokinase via NMR-based screening. , 2000, Journal of medicinal chemistry.

[6]  F. Blasi.  The urokinase receptor. A cell surface, regulated chemokine , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[7]  J. Hamilton,et al.  Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. , 2002, The American journal of pathology.

[8]  B. Sobel,et al.  Augmented urokinase receptor expression in atheroma. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[9]  S. Rabbani,et al.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.

[10]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[11]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[12]  B. Risberg,et al.  Urokinase Plasminogen Activator Colocalizes with CD25+ Cells in Atherosclerotic Vessels , 1998, Journal of Vascular Research.

[13]  B. Nielsen,et al.  Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[14]  M. Renatus,et al.  3-Amidinophenylalanine-based inhibitors of urokinase. , 1999, Bioorganic & medicinal chemistry letters.

[15]  O. Saksela,et al.  Plasminogen activation and regulation of pericellular proteolysis. , 1985, Biochimica et biophysica acta.

[16]  R. DesJarlais,et al.  Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[17]  J. Smit,et al.  Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system. , 1999, Thyroid : official journal of the American Thyroid Association.

[18]  B. Katz,et al.  Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. , 2001, Journal of medicinal chemistry.

[19]  J. Vassalli.  The Urokinase Receptor , 1994 .

[20]  V. Giranda,et al.  Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. , 2004, Journal of medicinal chemistry.

[21]  R. Huber,et al.  Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. , 1998, Journal of medicinal chemistry.

[22]  K. Wilson.  Synthesis of Thiophene‐2‐carboxamidines Containing 2‐Aminothiazoles and their Biological Evaluation as Urokinase Inhibitors. , 2001 .

[23]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[24]  K. Preissner,et al.  Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Andrew Smellie,et al.  Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..

[26]  R. Mackman.  2‐(2‐Hydroxy‐3‐alkoxyphenyl)‐1H‐benzimidazole‐5‐carboxamidine Derivatives as Potent and Selective Urokinase‐Type Plasminogen Activator Inhibitors. , 2002 .

[27]  J. Quigley,et al.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior , 1990, Cancer and Metastasis Reviews.

[28]  P. Fish,et al.  Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. , 2004, Bioorganic & medicinal chemistry letters.

[29]  W. Bell,et al.  The Fibrinolytic System in Neoplasia , 1996, Seminars in thrombosis and hemostasis.

[30]  V. Giranda,et al.  Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[31]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[32]  J. Greer,et al.  Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. , 1990, Journal of medicinal chemistry.

[33]  Milan Bruncko,et al.  Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. , 2005, Bioorganic & medicinal chemistry letters.

[34]  K. Preissner,et al.  The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: implications for cardiovascular function , 1999, Basic Research in Cardiology.

[35]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[36]  W. Gunzler.  The primary structure of high molecular mass urokinase from human urine , 1982 .

[37]  B. Katz,et al.  2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. , 2002, Bioorganic & medicinal chemistry letters.